# Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics

> **NCT02744820** · PHASE1 · TERMINATED · sponsor: **Genmedica Therapeutics S.L.** · enrollment: 34 (actual)

## Conditions studied

- Healthy
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** GMC-252-L-Lysine Salt
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02744820
- **Lead sponsor:** Genmedica Therapeutics S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** It was considered by the sponsor that the study objective has been met by dosing 13 instead of 15 patients
- **Last updated:** 2017-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02744820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02744820, "Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02744820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*